SGCB and pulmonary arterial hypertension: In view of this, it would of great interest to evaluate the combined anti-fibrotic effects of RLX with the new generation NO-independent sGC stimulators (BAY 41-2272; Beyer et al., 2015) and/or cGMP analogs (8-Br-cGMP; Rivero-Vilches et al., 2003), the former demonstrating excellent safety and tolerability in phase III trials in patients with pulmonary hypertension.